fda compounding semaglutide warning letters news GLP-1 Compounding: When Innovation May Mean Liability Out of Shortage, Into Controversy:

When medications for weight management are used as an adjunct to lifestyle intervention, they offer a rational pathway not only to weight loss but also to the treatment and prevention of cardiometabolic disease

Such marketing will have appeal for the portion of people, able to achieve health benefits by making healthy lifestyle changes, who are opting instead for the GLP-1 route to results

Another aspect is accounting for antioxidant capacity being influenced by factors unrelated to diabetes, co-existing infections for example

India Patent expires: March 2026 Adult population: 947 million Proportion of adults living with obesity a : 8% Proportion of adults living with diabetes b : 11% China Patent expires: March 2026 Adult population: 1.07 billion Proportion of adults living with obesity a : 9% Proportion of adults living with diabetes b : 12% Brazil Patent expires: March 2026 Adult population: 155 million Proportion of adults living with obesity a : 31% Proportion of adults living with diabetes b : 11% Trkiye Patent expires: 2026 Adult population: 59.0 million Proportion of adults living with obesity a : 36% Proportion of adults living with diabetes b : 16% Canada Patent expires: 2026 Adult population: 29.1 million Proportion of adults living with obesity a : 27% Proportion of adults living with diabetes b : 10% World Population: 8.23 billion More than 1 billion people in the world have a body mass index (BMI) 30 kg/m 2